Search
                    Utah Paid Clinical Trials
A listing of 1209  clinical trials  in Utah  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1165 - 1176 of 1209
        
                Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
                                
            
            
        Recruiting
                            
            
                This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                01/24/2024
            
            Locations: Lone Peak Family Health, Draper, Utah         
        
        
            Conditions: NASH - Nonalcoholic Steatohepatitis
        
            
        
    
                
                                    Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making
                                
            
            
        Recruiting
                            
            
                This study is a randomized clinical trial where participants (parents of a fetus or neonate diagnosed with a life-threatening congenital heart disease (CHD)) will randomly be assigned to either receiving a web-based decision aid (DA) alone, or receiving the decision aid that includes a values clarification exercise. Because of the novel use of decision aids in CHD in an acute setting, we will also compare participants receiving the DA in a randomized control trial to a prospective observational...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                01/22/2024
            
            Locations: Primary Children's Hospital Fetal and Pediatric Cardiology Clinics or Cardiac or Neonatal Intensive Care Units, Salt Lake City, Utah         
        
        
            Conditions: Patient Decision Aids, Congenital Heart Disease, Congenital Heart Defect
        
            
        
    
                
                                    Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
                                
            
            
        Recruiting
                            
            
                2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.             
        
        
    Gender:
                ALL
            Ages:
                Between 50 years and 80 years
            Trial Updated:
                01/12/2024
            
            Locations: University Of Utah Health, Salt Lake City, Utah         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
                                
            
            
        Recruiting
                            
            
                FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.             
        
        
    Gender:
                ALL
            Ages:
                Between 6 months and 25 years
            Trial Updated:
                12/21/2023
            
            Locations: University of Utah, Salt Lake City, Utah         
        
        
            Conditions: Low-grade Glioma, Advanced Solid Tumor
        
            
        
    
                
                                    Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
                                
            
            
        Recruiting
                            
            
                This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/15/2023
            
            Locations: START Mountain Region, West Valley City, Utah         
        
        
            Conditions: Tumor, Solid, Tumor, Advanced Solid Tumor
        
            
        
    
                
                                    Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
                                
            
            
        Recruiting
                            
            
                The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/29/2023
            
            Locations: Huntsman Cancer Institute, University of Utah 2000 Circle of Hope, Salt Lake City, Utah         
        
        
            Conditions: Melanoma Stage IIIB/C
        
            
        
    
                
                                    Time Restricted Eating (TRE) Among Endometrial Cancer Patients
                                
            
            
        Recruiting
                            
            
                The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                11/28/2023
            
            Locations: Huntsman Cancer Institute, Salt Lake City, Utah         
        
        
            Conditions: Endometrial Cancer
        
            
        
    
                
                                    Pediatric Vasculitis Initiative
                                
            
            
        Recruiting
                            
            
                Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classifica...  Read More             
        
        
    Gender:
                ALL
            Ages:
                20 years and below
            Trial Updated:
                11/27/2023
            
            Locations: University of Utah / Primary Children's Hospital, Salt Lake City, Utah         
        
        
            Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis, Eosinophilic Granulomatosis With Polyangiitis
        
            
        
    
                
                                    RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
                                
            
            
        Recruiting
                            
            
                Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, morbidity and mortality burden. There are two important approaches to the management of AF: 1). Controlling ventricular response rate without attempting to terminate or prevent AF (rate control), and 2). Attempting to control and maintain sinus rhythm (rh...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/20/2023
            
            Locations: University of Utah, Salt Lake City, Utah         
        
        
            Conditions: Atrial Fibrillation Paroxysmal
        
            
        
    
                
                                    A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering
                                
            
            
        Recruiting
                            
            
                Anterior vertebral body tethering (AVBT) is a novel, minimally invasive, growth modulation technique that was recently approved by the FDA under a Humanitarian Device Exemption (HDE). The goal of AVBT is to control curve progression by applying compression on the convex side of the spine deformity. While there has been great initial enthusiasm about the technique as an alternate treatment option to spinal fusion for skeletally immature children with scoliosis, there is a need to better understan...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and below
            Trial Updated:
                11/14/2023
            
            Locations: Primary Children's Hospital, Salt Lake City, Utah         
        
        
            Conditions: Scoliosis Idiopathic
        
            
        
    
                
                                    Hand Sanitizer Use for Herpes Simplex Virus-1
                                
            
            
        Recruiting
                            
            
                The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 99 years
            Trial Updated:
                11/13/2023
            
            Locations: Cotton Creek Dental, Saint George, Utah         
        
        
            Conditions: Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
        
            
        
    
                
                                    Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
                                
            
            
        Recruiting
                            
            
                This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/10/2023
            
            Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah         
        
        
            Conditions: CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
        
            
        
    